Pay in 4 interest-free payments of $6.66 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Retatrutide, an investigational once-weekly triple agonist from Eli Lilly, targets three metabolic pathways (GLP-1, GIP, and glucagon)
Loren Pickart
Because there have been no large-scale human clinical trials, the full range of short-term and long-term side effects is unknown
After a few weeks of consistent use, many people notice their skin appears smoother and more youthful
Limited Clinical Safety Data : The human safety profile remains unclear because the evidence is primarily based on animal and laboratory studies rather than large-scale clinical trials
This article contains affiliate links
US$ 23.87
US$ 20.80
US$ 24.26
US$ 21.02
US$ 22.47
US$ 21.75
